A Phase II, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Parallel-Group, Multicenter Study To Evaluate The Efficacy And Safety Of Balovaptan In Adults With Post-Traumatic Stress Disorder
Latest Information Update: 23 Apr 2024
At a glance
- Drugs Balovaptan (Primary)
- Indications Post-traumatic stress disorders
- Focus Therapeutic Use
- Sponsors Roche
- 01 Dec 2023 Status changed from active, no longer recruiting to completed.
- 03 Sep 2023 Status changed from recruiting to active, no longer recruiting.
- 12 Mar 2023 Planned number of patients changed from 252 to 30.